BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karlsson AK, Saleh SN. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clin Cosmet Investig Dermatol 2017;10:325-39. [PMID: 28883738 DOI: 10.2147/CCID.S120877] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Broussard L, Howland A, Ryu S, Song K, Norris D, Armstrong CA, Song PI. Melanoma Cell Death Mechanisms. Chonnam Med J 2018;54:135-42. [PMID: 30288368 DOI: 10.4068/cmj.2018.54.3.135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
2 Faron A, Opheys NS, Nowak S, Sprinkart AM, Isaak A, Theis M, Mesropyan N, Endler C, Sirokay J, Pieper CC, Kuetting D, Attenberger U, Landsberg J, Luetkens JA. Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors. Diagnostics (Basel) 2021;11:2314. [PMID: 34943551 DOI: 10.3390/diagnostics11122314] [Reference Citation Analysis]
3 Luo H, Zhang T, Cheng P, Li D, Ogorodniitchouk O, Lahmamssi C, Wang G, Lan M. Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors. Oncol Lett 2020;20:2525-36. [PMID: 32782571 DOI: 10.3892/ol.2020.11858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mccarthy MW, Walsh TJ. Checkpoint inhibitors and the risk of infection. Expert Review of Precision Medicine and Drug Development 2017;2:287-93. [DOI: 10.1080/23808993.2017.1380517] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Ahmed R, Muralidharan R, Srivastava A, Johnston SE, Zhao YD, Ekmekcioglu S, Munshi A, Ramesh R. Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells. Cancers (Basel) 2021;13:E166. [PMID: 33418925 DOI: 10.3390/cancers13020166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ikawa H, Koto M, Demizu Y, Saitoh JI, Suefuji H, Okimoto T, Ohno T, Shioyama Y, Takagi R, Hayashi K, Nemoto K, Nakano T, Kamada T. Multicenter study of carbon-ion radiation therapy for nonsquamous cell carcinomas of the oral cavity. Cancer Med 2019;8:5482-91. [PMID: 31369213 DOI: 10.1002/cam4.2408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6:143. [PMID: 29862232 DOI: 10.21037/atm.2018.02.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
9 Lurje I, Hammerich L, Tacke F. Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. Int J Mol Sci 2020;21:E7378. [PMID: 33036244 DOI: 10.3390/ijms21197378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
10 Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol 2020;12:1758835920937612. [PMID: 32728392 DOI: 10.1177/1758835920937612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
11 Sensi M, Berto M, Gentile S, Pinti M, Conti A, Pellacani G, Salvarani C, Cossarizza A, Bortolotti CA, Biscarini F. Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. Chem Commun (Camb) 2021;57:367-70. [PMID: 33325465 DOI: 10.1039/d0cc03399e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
12 Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129. [PMID: 30139382 DOI: 10.1186/s12943-018-0864-3] [Cited by in Crossref: 197] [Cited by in F6Publishing: 208] [Article Influence: 49.3] [Reference Citation Analysis]
13 Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res 2019;25:1650-63. [PMID: 30538110 DOI: 10.1158/1078-0432.CCR-18-1163] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
14 Galloway JE, Holderbaum AM, Arya N, Zhang S, Bodnar MS, Norman R, Carson WE, Yu L, Kendra KL, Burd CE. Impact of age-related T cell dynamics on the identification of biomarkers predictive of immunotherapy discontinuation: a prospective cohort study. Aging Cancer 2020;1:58-70. [PMID: 34337428 DOI: 10.1002/aac2.12012] [Reference Citation Analysis]
15 Liao XY, Liu CY, He JF, Wang LS, Zhang T. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy. Oncol Lett 2019;18:5011-21. [PMID: 31612012 DOI: 10.3892/ol.2019.10893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 Wei KZ, Baxter M, Casasola R. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. Melanoma Manag 2019;6:MMT13. [PMID: 31236205 DOI: 10.2217/mmt-2018-0009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers (Basel) 2019;11:E971. [PMID: 31336704 DOI: 10.3390/cancers11070971] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
18 Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, Diede SJ, Carlino MS, Joshua AM. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer 2021;144:182-91. [PMID: 33360855 DOI: 10.1016/j.ejca.2020.11.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Campana LG, Peric B, Mascherini M, Spina R, Kunte C, Kis E, Rozsa P, Quaglino P, Jones RP, Clover AJP, Curatolo P, Giorgione R, Cemazar M, Terlizzi F, Bosnjak M, Sersa G. Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry. Cancers (Basel) 2021;13:4289. [PMID: 34503099 DOI: 10.3390/cancers13174289] [Reference Citation Analysis]
20 Cerqueira OLD, Antunes F, Assis NG, Cardoso EC, Clavijo-salomón MA, Domingues AC, Tessarollo NG, Strauss BE. Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. Front Mol Biosci 2022;9:777775. [DOI: 10.3389/fmolb.2022.777775] [Reference Citation Analysis]
21 Ikawa H, Koto M, Hayashi K, Tonogi M, Takagi R, Nomura T, Tsuji H, Kamada T. Feasibility of carbon-ion radiotherapy for oral non-squamous cell carcinomas. Head Neck 2019;41:1795-803. [PMID: 30676669 DOI: 10.1002/hed.25618] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Zhang L, Wang J, Zhang B, Chu Q, Su C, Wu H, Chen X, Wang B, Yin Y, Zhu B, Sun J. Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey. Front Pharmacol 2021;12:583126. [PMID: 33841138 DOI: 10.3389/fphar.2021.583126] [Reference Citation Analysis]
23 Wang X, Wang P, Zhao Z, Mao Q, Yu J, Li M. A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Ther Adv Med Oncol 2020;12:1758835920926822. [PMID: 32518598 DOI: 10.1177/1758835920926822] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
24 Failmezger H, Muralidhar S, Rullan A, de Andrea CE, Sahai E, Yuan Y. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology. Cancer Res 2020;80:1199-209. [PMID: 31874858 DOI: 10.1158/0008-5472.CAN-19-2268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
25 Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, Chung CH, Chen Y, Huang B, Davis CB, Toffalorio F, Thall A, Powell SF. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer 2019;7:342. [PMID: 31801624 DOI: 10.1186/s40425-019-0815-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
26 Wang L, Liu Z, Zhang W, Zhang A, Qu P. PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis. Biomed Res Int 2021;2021:9923434. [PMID: 34124265 DOI: 10.1155/2021/9923434] [Reference Citation Analysis]